TLDR
- United Therapeutics (UTHR) stock rose about 13% after a Delaware federal court ruled in its favor in a patent case.
- The court found that Liquidia infringed two patent claims tied to inhaled treprostinil treatments.
- Liquidia (LQDA) shares dropped sharply on the ruling, falling more than 50%.
- Both companies must submit proposed legal remedies to the court within one week.
- UTHR is trading near its 52-week high and is up about 10% for the year.
United Therapeutics (NASDAQ: UTHR) stock jumped 13% on Wednesday after a federal court ruled in the company’s favor in a long-running patent dispute. The stock traded near $543.86 per share, close to its 52-week high of $596.76 set back in May 2026.
United Therapeutics Corporation, UTHR
The U.S. District Court for the District of Delaware found that rival Liquidia Corporation infringed on two patent claims held by United Therapeutics. The claims cover treatment of pulmonary hypertension with interstitial lung disease using inhaled treprostinil, including dry powder formulations.
Liquidia stock cratered on the news, falling more than 50% in a single session.
What the Court Decided
The court ruled that claims 1 and 14 of U.S. Patent No. 11,826,327 were valid and infringed by Liquidia’s Yutrepia inhalation powder. It invalidated the four other claims that United Therapeutics had asserted in the case.
Both companies now have one week to submit proposed legal remedies to the court. United Therapeutics has already asked for injunctive relief in its post-trial briefs. That could limit how widely Liquidia is able to sell Yutrepia going forward.
Yutrepia received FDA approval in 2025 to treat both pulmonary arterial hypertension and PH-ILD. United Therapeutics brought the lawsuit under the Hatch-Waxman Act, a law that governs patent disputes between brand name and generic drug makers.
Liquidia’s Response
Liquidia CEO Roger Jeffs said the company disagrees with the ruling on claims 1 and 14. He confirmed Liquidia plans to pursue an appeal.
Jeffs also said Liquidia intends to submit a supplement to Yutrepia’s New Drug Application. The goal would be to remove the PH-ILD indication from the drug’s label entirely.
Liquidia said it cannot yet estimate the financial impact of the ruling. The company pointed to several unknown variables, including the appeals process and further court proceedings still to come.
Possible outcomes range from a narrower label for Yutrepia to broader limits on the product’s availability in the market.
This is not the first big move for United Therapeutics stock this year. Six days earlier, the stock dropped 4% after Goldman Sachs analyst Andrea Newkirk started coverage with a Sell rating.
United Therapeutics shares don’t swing wildly very often. The stock has only moved more than 5% in a single day five times over the past year, so this week’s jump stands out.
The stock is up about 10% since the start of the year. Investors who put $1,000 into United Therapeutics five years ago would now have an investment worth roughly $2,947.
The case now moves to its next phase, with both companies due to file proposed remedies within the week.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
